输血相关免疫调节机制研究进展  

Research Advance on Transfusion-related Immunomodulation——Review

作　　者：朱鑫方[1] 夏荣[1] 

机构地区：[1]复旦大学附属华山医院输血科,上海200040

出　　处：《中国实验血液学杂志》2010年第1期268-272,共5页Journal of Experimental Hematology

摘　　要：同种异体输血(allogenic blood transfusion,ABT)发挥临床治疗作用的同时,也会发生很多免疫相关的副作用,如术后感染率上升、恶性肿瘤切除复发率增加等。血制品中的同种异基因单核细胞表面的CD200分子、白细胞及储存过程中白细胞脱落的sHLA和sFasL、血清中的生物活性分子等与输血相关免疫调节(transfusion-relatedimmunomodulation,TRIM)的发生均有一定联系。临床对照试验,实验室研究及动物模型显示:克隆删除、诱导无能、免疫抑制是TRIM发生的效应机制。本文就TRIM的发生机制、诱导TRIM发生的介质的研究进展进行了综述。As allogeneic blood transfusion plays a role in clinical treatment eflects, it also produces a number of immune-related side effects, such as the increased rate of postoperative infection, the rising relapse rate of malignant resection and so on. All those factors, such as CD200 surface molecule of allogeneic mononuclear cells, interleukin, sHLA and sFasL which are detached from the leukocyte surface during the period of storage, and serum bioactive molecules related to a certain degree with the occurrence of transfusion-related immunomodulation （TRIM）. The clinical controlled trials, laboratory researches and animal models demonstrated that cloning deletion, induction of anergy and immune suppression are the three major mechanisms of TRIM. In this artile, the research advances on mechanism of TRIM and the mediators inducing TRIM are reviewed.

关 键 词：同种异体输血 输血相关免疫调节 CD200 sHLA SFASL 

分 类 号：R457.1[医药卫生—治疗学]